LIVIVO - Suchergebnisse -

Suchergebnis

Treffer 1 - 8 von insgesamt 8

Suchoptionen

Artikel ; Online: Efficacy and safety of offline extracorporeal photopheresis in cutaneous T-cell lymphomas: A retrospective study.

Moreno-Vílchez, Carlos / Muniesa, Cristina / González-Barca, Eva / García-Muñoz, Nadia / Ortega-Sánchez, Sandra / Servitje, Octavio

Photodermatology, photoimmunology & photomedicine

2023 Band 39, Heft 6, Seite(n) 667–669

Mesh-Begriff(e)	Humans ; Retrospective Studies ; Photopheresis ; Lymphoma, T-Cell, Cutaneous/therapy ; Skin Neoplasms/therapy
Sprache	Englisch
Erscheinungsdatum	2023-07-19
Erscheinungsland	England
Dokumenttyp	Letter
ZDB-ID	1028855-7
ISSN	1600-0781 ; 0108-9684 ; 0905-4383
ISSN (online)	1600-0781
ISSN	0108-9684 ; 0905-4383
DOI	10.1111/phpp.12901
Datenquelle	MEDical Literature Analysis and Retrieval System OnLINE

Volltext online

Zugriff für angemeldete ZB MED Nutzerinnen und Nutzer

Zusatzmaterialien

Verfügbar in ZB MED Köln/Königswinter

Zs.A 1951: Hefte anzeigen

Standort:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Über subito bestellen

Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

Details ▾

Artikel ; Online: Linfoma cutáneo asociado a metotrexato en un paciente con artritis reumatoide.

Antón Vázquez, Vanesa / Corominas, Héctor / García Muñoz, Nadia / Hebe Petiti, Gisela

Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria

2018 Band 42, Heft 1, Seite(n) 35–36

Titelübersetzung	Cutaneous lymphoma associated with methotrexate in a patient with rheumatoid arthritis.
Mesh-Begriff(e)	Aged ; Antirheumatic Agents/adverse effects ; Antirheumatic Agents/therapeutic use ; Arthritis, Rheumatoid/complications ; Arthritis, Rheumatoid/drug therapy ; Humans ; Lymphoma, B-Cell/chemically induced ; Male ; Methotrexate/adverse effects ; Methotrexate/therapeutic use ; Skin Neoplasms/chemically induced
Chemische Substanzen	Antirheumatic Agents ; Methotrexate (YL5FZ2Y5U1)
Sprache	Spanisch
Erscheinungsdatum	2018-01-01
Erscheinungsland	Spain
Dokumenttyp	Case Reports ; Journal Article
ZDB-ID	1122680-8
ISSN	2171-8695 ; 1130-6343
ISSN (online)	2171-8695
ISSN	1130-6343
DOI	10.7399/fh.10898
Datenquelle	MEDical Literature Analysis and Retrieval System OnLINE

Zusatzmaterialien

Verfügbar in ZB MED Köln/Königswinter

Zs.A 3450: Hefte anzeigen

Standort:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Über subito bestellen

Details ▾
- Im ZB MED-Bestand
- Kostenpflichtig bestellen

Artikel ; Online: A hub-and-spoke model to deliver effective access to chimeric antigen receptor T-cell therapy in a public health network: the Catalan Blood and Tissue Bank experience.

Fernandez-Sojo, Jesus / Delgadillo, Joaquim / Vives, Joaquim / Rodriguez, Luciano / Mendoza, Ana / Azqueta, Carmen / Garcia-Buendia, Ana / Valdivia, Elena / Martorell, Lluis / Rubio-Lopez, Nuria / Linares, Mónica / Alonso, Sofia / Ancochea, Agueda / García-Rey, Enric / García-Muñoz, Nadia / Medina, Laura / Querol, Sergio

Cytotherapy

2022 Band 25, Heft 1, Seite(n) 14–19

Abstract: Background aims: To describe and analyze whether a hub-and-spoke organizational model could efficiently provide access to chimeric antigen receptor (CAR) T-cell therapy within a network of academic hospitals and address the growing demands of this ... ...

Abstract	Background aims: To describe and analyze whether a hub-and-spoke organizational model could efficiently provide access to chimeric antigen receptor (CAR) T-cell therapy within a network of academic hospitals and address the growing demands of this complex and specialized activity. Methods: The authors performed a retrospective evaluation of activity within the Catalan Blood and Tissue Bank network, which was established for hematopoietic stem cell transplantation to serve six CAR T-cell programs in academic hospitals of the Catalan Health Service. Procedures at six hospitals were followed from 2016 to 2021. Collection shipments of starting materials, CAR T-cell returns for storage and infusions for either clinical trials or commercial use were evaluated. Results: A total of 348 leukocytapheresis procedures were performed, 39% of which were delivered fresh and 61% of which were cryopreserved. The network was linked to seven advanced therapy medicinal product manufacturers. After production, 313 CAR T-cell products were shipped back to the central cryogenic medicine warehouse located in the hub. Of the units received, 90% were eventually administered to patients. A total of 281 patients were treated during this period, 45% in clinical trials and the rest with commercially available CAR T-cell therapies. Conclusions: A hub-and-spoke organizational model based on an existing hematopoietic stem cell transplantation program is efficient in incorporating CAR T-cell therapy into a public health hospital network. Rapid access and support of growing activity enabled 281 patients to receive CAR T cells during the study period.
Mesh-Begriff(e)	Humans ; Immunotherapy, Adoptive/methods ; Receptors, Chimeric Antigen ; Public Health ; Retrospective Studies ; Hematopoietic Stem Cell Transplantation ; Receptors, Antigen, T-Cell
Chemische Substanzen	Receptors, Chimeric Antigen ; Receptors, Antigen, T-Cell
Sprache	Englisch
Erscheinungsdatum	2022-08-27
Erscheinungsland	England
Dokumenttyp	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2039821-9
ISSN	1477-2566 ; 1465-3249
ISSN (online)	1477-2566
ISSN	1465-3249
DOI	10.1016/j.jcyt.2022.07.011
Datenquelle	MEDical Literature Analysis and Retrieval System OnLINE

Volltext online

Zugriff für angemeldete ZB MED Nutzerinnen und Nutzer

Zusatzmaterialien

Verfügbar in ZB MED Köln/Königswinter

Zs.A 5601: Hefte anzeigen

Standort:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Über subito bestellen

Details ▾

Artikel ; Online: Evaluation of Humoral and Cellular Immune Responses to the SARS-CoV-2 Vaccine in Patients With Common Variable Immunodeficiency Phenotype and Patient Receiving B-Cell Depletion Therapy.

Antolí, Arnau / Rocamora-Blanch, Gemma / Framil, Mario / Mas-Bosch, Virgínia / Navarro, Sergio / Bermudez, Carla / Martinez-Yelamos, Sergio / Dopico, Eva / Calatayud, Laura / Garcia-Muñoz, Nadia / Hernández-Benítez, Luis Humberto / Riera-Mestre, Antoni / Bas, Jordi / Masuet-Aumatell, Cristina / Rigo-Bonnin, Raúl / Morandeira, Francisco / Solanich, Xavier

Frontiers in immunology

2022 Band 13, Seite(n) 895209

Abstract: Introduction: SARS-CoV-2 vaccines' effectiveness is not yet clearly known in immunocompromised patients. This study aims to assess the humoral and cellular specific immune response to SARS-CoV-2 vaccines and the predictors of poor response in patients ... ...

Abstract	Introduction: SARS-CoV-2 vaccines' effectiveness is not yet clearly known in immunocompromised patients. This study aims to assess the humoral and cellular specific immune response to SARS-CoV-2 vaccines and the predictors of poor response in patients with common variable immunodeficiency (CVID) phenotype and in patients treated with B-cell depletion therapies (BCDT), as well as the safety of these vaccines. Methods: From March to September 2021, we performed a prospective study of all adult patients who would receive the SARS-CoV-2 vaccination and were previously diagnosed with (i) a CVID syndrome (CVID phenotype group; n=28) or (ii) multiple sclerosis (MS) treated with B-cell depleting therapies three to six months before vaccination (BCD group; n=24). Participants with prior SARS-CoV-2 infection; or prior SARS-CoV-2 vaccine administration; or use of any immunosuppressant (except BCDT in MS group) were excluded. A group of subjects without any medical condition that confers immunosuppression and who met all study criteria was also assessed (control group; n=14). A chemiluminescence immunoassay was used to determine pre- and post-SARS-CoV-2 vaccine anti-S IgG antibodies. T-cell specific response was assessed by analysis of pre- and post-SARS-CoV-2 vaccination blood samples with an interferon-gamma release assay. The baseline blood sample also included several biochemical, haematological and immunological analyses. Results: SARS-CoV-2 vaccines are safe in immunocompromised patients, although their effectiveness was lower than in healthy individuals. CVID phenotype patients showed impaired humoral (29%) and cellular (29%) response, while BCD patients fundamentally presented humoral failure (54%). Low IgA values, low CD19+ peripheral B cells, low switched memory B cells, and a low CD4+/CD8+ ratio were predictors of inadequate specific antibody response in CVID phenotype patients. No factor was found to predict poor cellular response in CVID phenotype patients, nor a defective humoral or cellular response in BCD patients. Conclusion: The effectiveness of SARS-CoV-2 vaccines in CVID phenotype and BCD patients is lower than in healthy individuals. Knowledge of predictive factors of humoral and cellular response failure in immunocompromised patients could be very useful in clinical practice, and thus, studies in this regard are clearly needed.
Mesh-Begriff(e)	Antibodies, Viral ; COVID-19 ; COVID-19 Vaccines ; Common Variable Immunodeficiency/therapy ; Humans ; Immunity, Cellular ; Phenotype ; Prospective Studies ; SARS-CoV-2
Chemische Substanzen	Antibodies, Viral ; COVID-19 Vaccines
Sprache	Englisch
Erscheinungsdatum	2022-04-29
Erscheinungsland	Switzerland
Dokumenttyp	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2606827-8
ISSN	1664-3224 ; 1664-3224
ISSN (online)	1664-3224
ISSN	1664-3224
DOI	10.3389/fimmu.2022.895209
Datenquelle	MEDical Literature Analysis and Retrieval System OnLINE

Zusatzmaterialien

Über subito bestellen

Details ▾
- Kostenpflichtig bestellen

Artikel ; Online: Leukocytapheresis variables and transit time for allogeneic cryopreserved hpc: better safe than sorry.

Fernandez-Sojo, Jesus / Horton, Roger / Cid, Joan / Azqueta, Carmen / Garcia-Buendia, Ana / Valdivia, Elena / Martorell, Lluis / Rubio-Lopez, Nuria / Codinach, Margarita / Aran, Gemma / Marsal, Julia / Mussetti, Alberto / Martino, Rodrigo / Diaz-de-Heredia, Cristina / Ferra, Christelle / Valcarcel, David / Linares, Mónica / Ancochea, Agueda / García-Rey, Enric /

García-Muñoz, Nadia / Medina, Laura / Carreras, Enric / Villa, Juliana / Lozano, Miquel / Gibson, Daniel / Querol, Sergio

Bone marrow transplantation

2022 Band 57, Heft 10, Seite(n) 1531–1538

Abstract: Cryopreservation was recommended to ensure continuity in allogeneic hematopoietic progenitor cells (HPC) transplantation during the COVID-19 pandemic. Several groups have shown no impact on clinical outcomes for patients who underwent HPC transplantation ...

Abstract	Cryopreservation was recommended to ensure continuity in allogeneic hematopoietic progenitor cells (HPC) transplantation during the COVID-19 pandemic. Several groups have shown no impact on clinical outcomes for patients who underwent HPC transplantation with cryopreserved products during the first months of this pandemic. However, concerns about quality control attributes after cryopreservation have been raised. We investigated, in 155 allogeneic peripheral blood cryopreserved HPC, leukocytapheresis characteristics influencing viable CD34
Mesh-Begriff(e)	Antigens, CD34/analysis ; COVID-19 ; Cell Survival ; Cryopreservation ; Hematopoietic Stem Cell Transplantation ; Hematopoietic Stem Cells ; Humans ; Leukapheresis ; Pandemics
Chemische Substanzen	Antigens, CD34
Sprache	Englisch
Erscheinungsdatum	2022-07-08
Erscheinungsland	England
Dokumenttyp	Journal Article
ZDB-ID	632854-4
ISSN	1476-5365 ; 0268-3369 ; 0951-3078
ISSN (online)	1476-5365
ISSN	0268-3369 ; 0951-3078
DOI	10.1038/s41409-022-01750-2
Datenquelle	MEDical Literature Analysis and Retrieval System OnLINE

Volltext online

Zugriff für angemeldete ZB MED Nutzerinnen und Nutzer

Zusatzmaterialien

Verfügbar in ZB MED Köln/Königswinter

Zs.A 2168: Hefte anzeigen

Standort:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Über subito bestellen

Details ▾

Artikel ; Online: Post thawing viable CD34+ Cells dose is a better predictor of clinical outcome in lymphoma patients undergoing autologous stem cell transplantation.

Fernandez-Sojo, Jesus / Cid, Joan / Azqueta, Carmen / Valdivia, Elena / Martorell, Lluis / Codinach, Margarita / Marsal, Julia / Mussetti, Alberto / Esquirol, Albert / Trabazo, Maria / Benitez, Maria Isabel / Ferra, Christelle / Fox, Maria Laura / Linares, Mónica / Alonso, Eva / García-Rey, Enric / García-Muñoz, Nadia / Medina, Laura / Castillo-Flores, Nerea /

Vall-Llovera, Ferran / Garcia, Antoni / Pinacho, Asuncion / Talarn, Carme / Arroba, Jose Garcia / Coll, Rosa / Santos, Mireia / Valero, Oliver / Carreras, Enric / Lozano, Miquel / Querol, Sergio

Bone marrow transplantation

2022 Band 57, Heft 8, Seite(n) 1341–1343

Mesh-Begriff(e)	Antigens, CD34 ; Hematopoietic Stem Cell Transplantation ; Humans ; Lymphoma/therapy ; Peripheral Blood Stem Cell Transplantation ; Transplantation, Autologous
Chemische Substanzen	Antigens, CD34
Sprache	Englisch
Erscheinungsdatum	2022-05-25
Erscheinungsland	England
Dokumenttyp	Letter
ZDB-ID	632854-4
ISSN	1476-5365 ; 0268-3369 ; 0951-3078
ISSN (online)	1476-5365
ISSN	0268-3369 ; 0951-3078
DOI	10.1038/s41409-022-01722-6
Datenquelle	MEDical Literature Analysis and Retrieval System OnLINE

Volltext online

Zugriff für angemeldete ZB MED Nutzerinnen und Nutzer

Zusatzmaterialien

Verfügbar in ZB MED Köln/Königswinter

Zs.A 2168: Hefte anzeigen

Standort:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Über subito bestellen

Details ▾

Artikel ; Online: Cryopreservation of unrelated donor hematopoietic stem cells: the right answer for transplantations during the COVID-19 pandemic?

Fernandez-Sojo, Jesus / Azqueta, Carmen / Valdivia, Elena / Martorell, Lluis / Medina-Boronat, Laura / Martínez-Llonch, Nuria / Torrents, Silvia / Codinach, Margarita / Canals, Carme / Elorza, Izaskun / Parody, Rocio / Martino, Rodrigo / Trabazo, Maria / Díaz de Heredia, Cristina / Ferra, Christelle / Valcárcel, David / Linares, Mónica / Ancochea, Águeda / García-Rey, Enric /

García-Muñoz, Nadia / Medina, Laura / Castillo, Nerea / Carreras, Enric / Villa, Juliana / Querol, Sergio

Bone marrow transplantation

2021 Band 56, Heft 10, Seite(n) 2489–2496

Abstract: Cryopreservation was recommended to ensure continuity of unrelated donor (UD) hematopoietic stem cell transplantation (HSCT) during COVID-19 pandemic. However, its impact on clinical outcomes and feasibility was not well known. We compared 32 patients ... ...

Abstract	Cryopreservation was recommended to ensure continuity of unrelated donor (UD) hematopoietic stem cell transplantation (HSCT) during COVID-19 pandemic. However, its impact on clinical outcomes and feasibility was not well known. We compared 32 patients who underwent UD HSCT using cryopreserved peripheral blood stem cells (PBSC) during the COVID-19 pandemic with 32 patients who underwent UD HSCT using fresh PBSC in the previous period. Median neutrophil engraftment was 17.5 and 17.0 days with cryopreserved and fresh grafts, respectively. Non-significant delays were found in platelet recovery days (25.5 versus 19.0; P = 0.192) and full donor chimerism days (35.0 and 31.5; P = 0.872) using cryopreserved PBSC. The rate of acute graft-versus-host disease at 100 days was 41% (95% CI [21-55%]) in cryopreserved group versus 31% (95% CI [13-46%]) in fresh group (P = 0.380). One-hundred days progression-relapse free survival and overall survival did not differ significantly. During COVID-19 pandemic, six frozen UD donations were not transfused and logistical and clinical issues regarding cryopreservation procedure, packaging, and transporting appeared. In summary, UD HSCT with cryopreserved PBSC was safe during this challenging time. More efforts are needed to ensure that all frozen grafts are transplanted and cryopreservation requirements are harmonized.
Mesh-Begriff(e)	COVID-19 ; Cryopreservation ; Graft vs Host Disease ; Hematopoietic Stem Cell Transplantation ; Hematopoietic Stem Cells ; Humans ; Pandemics ; SARS-CoV-2 ; Unrelated Donors
Sprache	Englisch
Erscheinungsdatum	2021-06-14
Erscheinungsland	England
Dokumenttyp	Journal Article
ZDB-ID	632854-4
ISSN	1476-5365 ; 0268-3369 ; 0951-3078
ISSN (online)	1476-5365
ISSN	0268-3369 ; 0951-3078
DOI	10.1038/s41409-021-01367-x
Datenquelle	MEDical Literature Analysis and Retrieval System OnLINE

Volltext online

Zugriff für angemeldete ZB MED Nutzerinnen und Nutzer

Zusatzmaterialien

Verfügbar in ZB MED Köln/Königswinter

Zs.A 2168: Hefte anzeigen

Standort:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Über subito bestellen

Details ▾

Artikel ; Online: Real-world effectiveness of caplacizumab vs standard of care in immune thrombotic thrombocytopenic purpura.

Pascual Izquierdo, Maria Cristina / Mingot-Castellano, Maria Eva / Kerguelen Fuentes, Ana Esther / García-Arroba Peinado, José / Cid, Joan / Jiménez, Moraima / Valcarcel, David / Gomez-Segui, Ines / de la Rubia, Javier / Martin, Paz / Goterris, Rosa / Hernández-Mateo, Luis M / Tallón Ruiz, Inmaculada / Varea, Sara / Fernández-Docampp, Marta / García-Muñoz, Nadia / Vara, Míriam / Fernández Zarzoso, Miguel / García-Candel, Faustino /

Blood advances

2022

Abstract: Immune thrombotic thrombocytopenic purpura (iTTP) is a thrombotic microangiopathy caused by anti-ADAMTS13 antibodies. Caplacizumab is approved for adults with an acute episode of iTTP in conjunction with PEX and immunosuppression. The objective of this ... ...

Abstract	Immune thrombotic thrombocytopenic purpura (iTTP) is a thrombotic microangiopathy caused by anti-ADAMTS13 antibodies. Caplacizumab is approved for adults with an acute episode of iTTP in conjunction with PEX and immunosuppression. The objective of this study is to analyze and compare the safety and efficacy of caplacizumab versus the standard of care and assess the effect of the concomitant use of rituximab. A retrospective study from the Spanish TTP Registry of patients treated with caplacizumab vs those who did not receive it was conducted. A total of 155 iTTP patients (77 caplacizumab, 78 no caplacizumab) were included. Patients initially treated with caplacizumab had fewer exacerbations (4.5% vs 20.5% p<0.05) and less refractoriness (4.5% vs 14.1% p<0.05) than those that were not treated. Time to clinical response was shorter when caplacizumab was used as initial treatment vs caplacizumab used after refractoriness or exacerbation. The multivariate analysis showed that its use in the first 3 days after plasma exchange (PEX) was associated with a lower number of PEX (OR 7.5, CI 2.3-12.7; p<0.05) and days of hospitalization (OR 11.2, CI 5.6-16.9; p<0.001) compared to standard therapy. There was no difference in time to clinical remission in patients treated with caplacizumab compared to the use of rituximab. No severe adverse event was described in the caplacizumab group. In summary, caplacizumab reduced exacerbations and refractoriness compared to standard of care regimens. When administered within the first 3 days after PEX it also provided a faster clinical response, reducing hospitalization time and the need for PEX.
Sprache	Englisch
Erscheinungsdatum	2022-08-05
Erscheinungsland	United States
Dokumenttyp	Journal Article
ZDB-ID	2915908-8
ISSN	2473-9537 ; 2473-9529
ISSN (online)	2473-9537
ISSN	2473-9529
DOI	10.1182/bloodadvances.2022008028
Datenquelle	MEDical Literature Analysis and Retrieval System OnLINE

Zusatzmaterialien

Verfügbar in ZB MED Köln/Königswinter

Zs.A 7153: Hefte anzeigen

Standort:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Über subito bestellen

Details ▾
- Im ZB MED-Bestand
- Kostenpflichtig bestellen

Zum Seitenanfang

Ihre letzten Suchen

Volltext online

Zusatzmaterialien

Kategorien

Verfügbar in ZB MED Köln/Königswinter

Über subito bestellen

Zusatzmaterialien

Kategorien

Verfügbar in ZB MED Köln/Königswinter

Über subito bestellen

Volltext online

Zusatzmaterialien

Kategorien

Verfügbar in ZB MED Köln/Königswinter

Über subito bestellen

Zusatzmaterialien

Kategorien

Über subito bestellen

Volltext online

Zusatzmaterialien

Kategorien

Verfügbar in ZB MED Köln/Königswinter

Über subito bestellen

Volltext online

Zusatzmaterialien

Kategorien

Verfügbar in ZB MED Köln/Königswinter

Über subito bestellen

Volltext online

Zusatzmaterialien

Kategorien

Verfügbar in ZB MED Köln/Königswinter

Über subito bestellen

Zusatzmaterialien

Kategorien

Verfügbar in ZB MED Köln/Königswinter

Über subito bestellen